



Universiteit
Leiden
The Netherlands

Cellular signaling in human cholesteatoma

Huisman, Margaretha Aleida

Citation


Huisman, M. A. (2007, January 24). *Cellular signaling in human cholesteatoma*. Retrieved from <https://hdl.handle.net/1887/9449>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/9449>

Note: To cite this publication please use the final published version (if applicable).



1

Chapter 1

General Introduction



General clinical, morphological, biological and molecular aspects of cholesteatoma.

Clinical aspects

Cholesteatoma is a benign, gradually expanding destructive epithelial lesion of the temporal bone. Several hypotheses for the pathogenesis of human cholesteatoma have been proposed of which the most important are¹:

- The congenital hypothesis: cholesteatoma originates from embryological ectoderm remnants in the petrous bone. This implies that cholesteatoma develop behind an intact tympanic membrane in patients without a history of aural infections.
- The metaplastic hypothesis: metaplastic changes of differentiated middle ear epithelium lead to the formation of a cornified cholesteatoma epithelium.
- Epidermal hypotheses: cholesteatoma is considered to be an intrusion of epithelium from the existing epidermal lining of the tympanic membrane or external auditory canal (ME) into the middle ear cleft, forming a pathological collision between keratinocytes and mucosa. This ME may invade into the middle ear by 1) invagination of the tympanic membrane (retraction hypothesis), 2) ingrowth over the edges of a tympanic membrane perforation (migration hypothesis) and 3) medial proliferation of the basal cells through an intact tympanic membrane (proliferation hypothesis). These epidermal hypotheses suppose a considerable migratory capacity of the cells of the external ear canal. In cholesteatoma genesis, a combination of these epidermal hypotheses seems plausible. This has indeed been proposed for the retraction- and proliferation hypotheses².

In this thesis acquired cholesteatoma will be investigated. The genesis of acquired cholesteatoma is based on the epidermal hypothesis. Acquired cholesteatoma will usually occur in combination with a chronic middle ear inflammation or infection. Clinical sequela may include destruction of the middle ear ossicles and other structures. When untreated, there is a risk of labyrinth involvement, which may result in vertigo and sensorineural hearing loss. Facial nerve dysfunction and intracranial injury, although rarely seen today, are serious complications³. Early detection of cholesteatoma is important but complicated, because the early symptoms are difficult to distinguish from chronic otitis without cholesteatoma. High-resolution computed tomography and magnetic resonance imaging may facilitate pre-operative identification of cholesteatoma, although surgical exploration remains the most effective way^{3,4}.

Histomorphological aspects

The epithelial compartment

The epithelium of cholesteatoma exhibits generally exhibits a heterogeneous thickness, with a majority of hypertrophic areas, adjacent to normal ones (Fig1A). The hypertrophic area is at least 3-5 times thicker than normal retro-auricular skin. This increased thickness is often not only due to the hypertrophic character of the epidermis but also to an increased number of cell layers. Focal

hyperproliferation is present but not restricted to the hypertrophic layers. In the hypertrophic layers a modification of keratinocyte morphology is often observed. Different keratinocytes exhibit a rounded shape with hypertrophic cytoplasm and a round nucleus. There are also keratinocytes with a spindle shape which are oriented towards the stratum corneum with elongated cytoplasm and an oval nucleus. The diameter of the hypertrophic cells is about twice the diameter of normal cells. The hypertrophic areas often show a significant widening of the intercellular space, which suggests alterations in the network of intercellular junction proteins. In the non-hypertrophic areas abnormally small keratinocytes are often present, with a polygonal shape and similar to that observed in the basal layer of the normal retro-auricular epidermis (Fig.1B). The cholesteatoma epithelium has parakeratotic features, which is defined by the presence of nucleated cells in the stratum corneum. Hyperkeratinization is a common phenomenon in cholesteatoma tissue. There is a generalized inflammatory reaction with infiltration of different types of inflammatory cells into the epithelial compartment. Clusters of polymorphonuclear granulocytes (PMNs) and macrophages are present in areas adjacent to the stratum corneum




Fig.1 HE staining of a cholesteatoma. Original magnification: 200 x. Figure 1A represents a hypertrophic area with round and spindle cells. Figure 1B represents a non-hypertrophic area with very small cells.

The subepithelial compartment

Basal membrane

Cholesteatoma basal membrane differs from that of normal skin. It is often disrupted in areas where inflammation is present. Immunohistochemical investigation reveals aberrant collagen 4 and laminin expression⁵. At the ultrastructural level, protrusions, duplications, thickening and disruptions of the lamina densa of the basement membrane were observed⁵.

The dermis

Epithelial papillary outgrowth is a common phenomenon. The dermis is hyalinized and shows disorganized supporting fibres such as collagens and elastin. Vascularization is two-fold when compared to normal skin⁶. Inflammation is often prominently present with abundant inflammatory cells including T-cells,

macrophages, lymphocytes, mast cells and PMNs.

Biological aspects.

Is cholesteatoma a skin disease?

The presence of keratinising stratified squamous epithelium within the middle ear cleft has led to the assumption that cholesteatoma epithelium may be classified as a skin disease. Its parakeratotic aspect may subclassify it into the group of skin diseases such as psoriasis, dermatitis, pityriasis lichenoides, or precancerous and malignant squamous lesions⁷.

Is cholesteatoma a malignancy?

It has been suggested that several morphological aspects of human cholesteatoma resemble those in pre-malignant and malignant skin diseases⁸. These aspects include: increased proliferation, atypical differentiation and chromosomal aberrations. However, cholesteatoma is not a malignancy because it is not invasive and metastases have never been demonstrated. We determined the expressions of proliferation and differentiation markers of cholesteatoma and compared these with the results of other studies of cholesteatoma, malignant, pre-malignant and benign skin diseases⁹⁻⁴⁰. We focussed on the immunohistochemical detection of the proliferation markers Ki-67 and PCNA, the suppressor gene p53 and the marker of differentiation involucrin. The results are shown in Table 1.

	refs	Ki67	refs	PCNA	refs	P53	refs	Involucrin
malignant	Cutaneous squamous cell carcinoma	9,10	11	12	13			
	Squamous cell carcinoma	14,15	15,16	15	14			
pre-malignant	Actinic keratosis	15,17,18	15,17	15,17	19			
	Bowen's disease	14,15,17	15,17	15,17,20	14			
	Keratoacanthoma	15	15	15	30			
non-malignant	Treatment resistant atopic dermatitis	21,22	16	23	24			
	Psoriasis vulgaris	14,25,26	16,25	25,26	14			
	Verruca vulgaris	15	15,26	15,27,28	29,30			
	Cholesteatoma	31-38	35,38	31,32,34-37	39,40			
	Normal skin	14,18,26	18	14-18	14			

positivity			
0-10%	10-25%	25-50%	>50%

Table 1. represents differential expression of the proliferation markers (Ki67, PCNA), p53 and a terminal differentiation marker (involucrin). The numbers refer to different immunohistochemical studies of malignant-, pre-malignant-, benign skin diseases, cholesteatoma and normal skin.

This table shows the tendency of malignant skin diseases to be hyperproliferative. Benign skin diseases often show increased differentiation⁴¹. When compared with normal skin, differentiation of cholesteatoma epithelium is increased but this should *de facto* be considered as evidence in favor of the benign character of the disease. It has been argued that proliferation in cholesteatoma epithelium is increased⁶. Compared with all skin diseases including benign tumours, however, the average proliferation rate is not increased. Albino *et al.*, who found only a marginally statistically significant difference in proliferation between cholesteatoma and retroauricular skin⁸, has previously discussed this. Investigation of the (increased)

proliferative rate of cholesteatoma keratinocytes in children led to the speculation that high cholesteatomal proliferation might be considered as an indication for aggressive (i.e. fast growing) clinical behavior^{42,43}. This view is not supported by other studies, which showed that clinically less aggressive cholesteatomas also have a high proliferation rate⁴⁴. The induction of proliferative cells in suprabasal layers of the cholesteatoma epidermis might imply a potential idiopathic response to external stimuli in the form of cytokines released by infiltrating inflammatory cells.

Ki-67 is expressed throughout all phases in the cell cycle and PCNA in the S-phase but, interestingly, in cholesteatoma epithelium PCNA expression levels are higher than those of Ki-67. It has been demonstrated that PCNA is not only associated with delta DNA polymerase but also with mismatch repair genes⁴⁵. We therefore hypothesize that in cholesteatoma, as a consequence of a possible DNA-damaging effect of inflammatory stress, the expression of PCNA could be higher than that of Ki-67.

In cholesteatoma Albino *et al.* have demonstrated normal diploid DNA contents. However, other studies have reported chromosomal aberrations, such as chromosome 8 aneuploidy and chromosome 7 triploidy^{46,47}. In these studies, fluorescence *in situ* hybridization (FISH) techniques have been used. It is of note that chronic inflammatory stress, which is a common phenomenon in cholesteatoma epithelium, can also induce chromosomal aneuploidy or triploidy. Kinne *et al.*, using the same techniques, have described similar chromosomal aberrations for chromosome 7 and 8 in chronic rheumatoid arthritis⁴⁸. Although in cholesteatoma no clonality studies have been done, we believe that cholesteatoma does not show inherent genetic instability, but that the reported chromosomal aberrations are more likely to be caused by chronic inflammatory stress.

Is cholesteatoma a defective wound healing- or an inflammatory process, or both? Pressure-induced invaginations, morphological changes of the tympanic membrane (TM) or even perforation of the TM result in enough damage to induce wound-healing processes⁸. It has also been suggested that the juxtapositioning of two different epithelia, epidermis and middle ear epithelium, might be regarded as a persisting epidermal defect¹.

Woundhealing in cholesteatoma

The different stages of epithelial wound healing are inflammation, proliferation and demonstrated to be present (Table 2)^{35,49-70}. Inflammation is illustrated by the recruitment and activation of different inflammatory cells in the subepithelial compartment^{6,8}. The proliferative phase of cholesteatoma is illustrated by focal hyperproliferative epithelial growth centres⁶. Migration of the newly formed tissue to the injured site is a characteristic of remodelling. The migratory character of keratinocytes in cholesteatoma epithelium has been reported⁷¹ and the increased presence of the α V integrin subunit in the epithelial/subepithelial interface may indicate the formation of new anchoring contacts necessary for keratinocyte motility⁷². Furthermore, it has been shown that cholesteatoma fibroblasts have a

highly migrative phenotype⁷³. Although features of remodelling are present in cholesteatoma, it is considered to be defective because it remains in the inflammatory phase⁸.

Recently, the presence of biofilms in cholesteatoma has been demonstrated⁷⁴.

Stage of wound healing	Involved cytokines of growth factors	References
The initiator of activation:	IL- 1	49-52
Maintenance of activation:	TNF-, including upregulation of: amphiregulin, TGF -, add. IL -1 , IL -1 receptor antagonist, epidermal growthfactor receptor (EGFR), EGF, KGF and ICAM	35,50,53-59
The activated phenotype responsible for additional signalling:	growth factors and cytokines including TGF , IL -3, IL-6, IL-8, G-CSF, GM-CSF and M-CSF. cell signaling processes: RAF/ ERK1/2 MAPK pathway, Ras -c-jun	35,60-64
The contractile cell, migration:	IFN-, MMPs	IFN ⁷ R:65,66-68
Extracellular matrix deposition; inhibition of cell proliferation= back to basics	TGF-, fibronectin and collagen.	35,57,62,69

Table 2. Represents different stages of epithelial wound healing according to Freedberg (70) and the relevant literature concerning cholesteatoma pathogenesis.

Biofilms are colonies of quiescent bacteria in a hydrated matrix of polysaccharides. In these biofilms the bacteria are protected against noxious micro-environmental conditions as well as high concentrations of antibiotics. Although encapsulated, bacteria can be released from the biofilm and converted into the planktonic and thus infective form. The presence of biofilms in cholesteatoma may be responsible for the chronic inflammation, caused by either the released planktonic bacteria or by the continuous released endotoxins⁷⁴ such as lipopolysaccharide (LPS). Adherence of bacteria to epithelial surfaces can induce cellular signaling and cytokine upregulation⁷⁵. Endotoxins are able to stimulate the keratinocytes of the middle ear epithelium to cytokine production⁷⁶, which may result in recurrent inflammation. However, this is not always the default course of events because not every patient reacts to the same degree to endotoxins. Innate or acquired immunological factors may account for this individual variation⁷⁷. When cytokines and growth factors from inflammatory cells and/or endotoxins are present they may induce metaplastic changes of the epithelium⁷⁸. This is in accordance with the metaplastic hypothesis proposing metaplastic changes of the differentiated middle ear epithelium. In contrast, to the metaplastic hypothesis however, cholesteatoma also presents without earlier inflammation notwithstanding the fact that it is associated with inflammation.

Whether cholesteatoma is an inflammation or a wound, why does it not heal?
 Many factors can impair healing, such as systemic and local factors⁷⁹. Systemic

factors may be very diverse, such as malnutrition, advanced age and diabetes. To our knowledge, it has not been proven that cholesteatoma do not heal due to systemic reasons. Local factors, which delay or prevent healing, include the presence of foreign bodies, tissue maceration, ischaemia and infection. Besides infection, which is a known phenomenon in cholesteatoma pathology, it is appealing to consider a foreign body as an inhibiting factor for wound healing. Cholesteatoma, which is a keratinized particle encapsulated in the middle ear, might be regarded as a *corpus alienum*. An immunological reaction is obvious and inflammation may be the consequence^{80,81}.

Of interest is also a report in which it has been demonstrated that wound fibroblasts generate a brisk TNF response to stimulation with LPS, while under the same conditions, normal dermal fibroblasts did not secrete any measurable amounts of TNF⁸². In cholesteatoma, the increased presence of LPS may therefore contribute to disordered wound healing⁸³.

In addition to systemic and local factors that impair healing, an imbalance between proteolytic enzymes and their inhibitors, or a reduction in tissue growth factors, seem to be of particular importance in chronic wounds. An imbalance between proteinases and their inhibitors may induce excessive proteinase activity, which can result in a chronic wound. Moreover, it has been suggested that growth factors can be depleted by proteases, which may also result in non-healing⁸⁴. In cholesteatoma different reports describe the increased presence of growth factors and proteases but their degree of activity or the presence of their inhibitors, has hardly been investigated and needs to be further explored.

Molecular aspects

In cholesteatoma, the result of the chronic inflammatory process is the presence of a plethora of inflammatory cytokines and growth factors, expressed by inflammatory cells and keratinocytes. The understanding of wound-healing mechanisms has progressed considerably in recent years^{85,86}. However, many questions remain, such as the considerable crosstalking in the system. Most wound signals control more than one cell activity but cell activity may also be a response to differential triggering⁸⁷. Moreover, it is certain that growth factor and matrix signals are not the only relevant influences. Changes of gap-junctional connections between keratinocytes at the healing margin⁸⁸ may coordinate cell proliferation and migration. Mechanical signals such as cell stretching or altered tensions at the wound-site may prove to be important alternative factors in wound healing. The presence of many inflammatory signaling proteins in the more or less enclosed area of the middle ear may result in an altered or confused signal transduction within the cholesteatoma epithelial- and sub epithelial cells. To our knowledge, studies on cellular signaling pathways in cholesteatoma have not been published. The aim of this thesis is to explore the main transduction signaling pathways in cholesteatoma. Because of the complexity of the system, this study is mainly focussed on MAPK-, Akt- and TGF- β - signaling pathways in cholesteatoma keratinocytes and the TGF- β -signaling in the stroma. The proteins that are involved in these signaling pathways will be discussed in the next chapters.

Aim and outline of this thesis

The main objective of this thesis is to investigate those protein signaling pathways in human cholesteatoma which may be involved in different aspects of cholesteatoma pathogenesis, such as hyperproliferation, aberrant differentiation and extra-cellular matrix deposition.

Aim of the study

The major objective of this study is to investigate cellular signaling pathways and the expression of different proteins in human cholesteatoma in order to answer the following questions:

1. Is increased proliferation in cholesteatoma compensated by increased apoptosis?
2. What are the signaling pathways that influence the proliferative activity of the keratinocytes?
3. What is the mechanism behind increased differentiation?
4. Which are the main processes leading to extra-cellular matrix alterations?
5. Are extra-cellular matrix alterations associated with aberrant epithelial characteristics? (Is there crosstalk between these?)
6. Can different pathogenic features of cholesteatoma be explained?

Content of the thesis

In this thesis we studied the signaling pathways in human cholesteatoma epithelium, which are involved in cellular proliferation, terminal differentiation, cell cycle arrest and apoptosis. We also investigated to which extent TGF- β 1, as the key factor involved in wound healing, is involved in both cholesteatoma epithelial and stromal cellular signaling.

Chapter 1 describes cholesteatoma from a general clinical, morphological and biological point of view.

In **chapter 2** the most important proteins involved in proliferation (Ki-67, PCNA), differentiation (involucrin) and cell cycle arrest (p53, p21^{cip1/waf1}) as well as the mechanism of apoptosis and the role of active caspase 3 are reviewed. In this chapter also the phenomenon cellular signaling is introduced including MAPK, pAKT and TGF- β signaling pathways.

Chapter 3 concerns the study of the expression level of different proteins involved in proliferation, cell cycle arrest and apoptosis and their association.

Chapter 4 provides evidence for an association of the expression of p21^{cip1/waf1} as a marker of cell cycle arrest and MAPK signaling.

In **chapter 5** we investigated the involvement of MAPK signaling in terminal differentiation.

Terminal differentiation of cholesteatoma epithelial cells as a survival mechanism is presented in **chapter 6**.

Chapter 7 describes TGF- β bioactivation in cholesteatoma epithelium as well as stroma.

The general discussion and summary are presented in **chapter 8**.

References

1. Vennix PPCA. Meatal epidermis, middle ear epithelium and cholesteatoma. Thesis, Leiden;1996
2. Sudhoff H, Tos M. Pathogenesis of attic cholesteatoma: clinical and immunohistochemical support for combination of retraction theory and proliferation theory. *Am J Otol.* 2000 Nov;21(6):786-92
3. Åberg B, Westin T, Tjellstrom A, Edstrom S. Clinical characteristics of cholesteatoma. *Am J Otolaryngol.* 1991 Sep-Oct;12(5):254-8.
4. Czerny C, Turetschek K, Duman M, Imhof H. Imaging of the middle ear. CT and MRI. *Radiologe.* 1997 Dec;37(12):945-53.
5. Bernal Sprekelsen M, Ebmeyer J, Anonopoulos A, Borkowski G, Sudhoff H. Alterations of the basal membrane in middle ear cholesteatoma. *Acta Otorrinolaringol Esp.* 2001 May;52(4):330-5
6. Olszewska E, Wagner M, Bernal-Sprekelsen M, Ebmeyer J, Dazert S, Hildmann H, Sudhoff H. Etiopathogenesis of cholesteatoma. *Eur Arch Otorhinolaryngol.* 2004 Jan;261(1):6-24. Epub 2003 Jun 27.
7. Hohl D. Expression patterns of loricrin in dermatological disorders. *Am J Dermatopathol.* 1993 Feb;15(1):20-7.
8. Albino AP, Kimmelman CP, Parisier SC. Cholesteatoma: a molecular and cellular puzzle. *Am J Otol.* 1998 Jan;19(1):7-19.
9. Kanitakis J, Narvaez D, Euvrard S, Faure M, Claudy A. Proliferation markers Ki67 and PCNA in cutaneous squamous cell carcinomas: lack of prognostic value. *Br J Dermatol.* 1997 Apr;136(4):643-4.
10. al-Sader MH, Doyle E, Kay EW, Bennett M, Walsh CB, Curran B, Milburn C, Leader M. Proliferation indexes-a comparison between cutaneous basal and squamous cell carcinomas.: *J Clin Pathol.* 1996 Jul;49(7):549-51
11. Fabbrocini G, Russo N, Pagliuca MC, Delfino M, Staibano S, Molea G, Mancini A, Virgili A, Valente MG, Bratina G, Galbiati S, Marzaduri A, Orlandi K, Bottoni U, Calvieri S, Di Landro A, Cainelli T, Delfino S, De Rosa G. p53, cyclin-D1, PCNA, AgNOR expression in squamous cell cancer of the lip: a multicenter study. *Photodermatol Photoimmunol Photomed.* 2000 Aug;16(4):172-7
12. O'Connor DP, Kay EW, Leader M, Murphy GM, Atkins GJ, Mabruk MJ. Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: correlation with human papillomaviruses? *Diagn Mol Pathol.* 2001 Sep;10(3):190-9.
13. Watanabe S, Ichikawa E, Takahashi H, Otsuka F. Changes of cytokeratin and involucrin expression in squamous cell carcinomas of the skin during progression to malignancy. *Br J Dermatol.* 1995 May;132(5):730-9.
14. Caldwell CJ, Hobbs C, McKee PH. The relationship of Ki67 and involucrin expression in proliferative, pre-neoplastic and neoplastic skin. *Clin Exp Dermatol.* 1997 Jan;22(1):11-6
15. Lu S, Tiekso J, Hietanen S, Syrjanen K, Havu VK, Syrjanen S. Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement. *Acta Derm Venereol.* 1999 Jul;79(4):268-73
16. Kawahira K. Immunohistochemical staining of proliferating cell nuclear antigen (PCNA) in malignant and nonmalignant skin diseases. *Arch Dermatol Res.* 1999 Jul-Aug;291(7-8):413-8.
17. Mitsuishi T, Kawana S, Kato T, Kawashima M. Human papillomavirus infection in actinic keratosis and bowen's disease: comparative study with expression of cell-cycle regulatory proteins p21(Waf1/Cip1), p53, PCNA, Ki-67, and Bcl-2 in positive and negative lesions. *Hum Pathol.* 2003 Sep;34(9):886-92.

18. Carpenter PM, Linden KG, McLaren CE, Li KT, Arain S, Barr RJ, Hite P, Sun JD, Meyskens FL Jr. Nuclear morphometry and molecular biomarkers of actinic keratosis, sun-damaged, and nonexposed skin. *Cancer Epidemiol Biomarkers Prev.* 2004 Dec;13(12):1996-2002.
19. Smoller BR, Krueger J, McNutt NS, Hsu A. "Activated" keratinocyte phenotype is unifying feature in conditions which predispose to squamous cell carcinoma of the skin. *Mod Pathol.* 1990 Mar;3(2):171-5.
20. Kawakami T, Soma Y, Mizoguchi M, Saito R. Analysis of p53, p21^(Waf1/Cip1) and TGF- β (3) immunohistochemical staining in Bowen's disease. *Dermatology.* 2001;202(1):9-15.
21. Sapuntsova SG, Melnikova NP, Deigin VI, Kozulin EA, Timoshin SS. Proliferative processes in the epidermis of patients with atopic dermatitis treated with thymodepressin. *Bull Exp Biol Med.* 2002 May;133(5):488-90
22. Van Erp PE, De Mare S, Rijzewijk JJ, Van de Kerkhof PC, Bauer FW. A sequential double immunoenzymic staining procedure to obtain cell kinetic information in normal and hyperproliferative epidermis. *Arch Dermatol Res.* 2001 Apr;293(4):178-83.
23. Breuckmann F, Pieck C, Kreuter A, Bacharach-Buhles M, Mannherz HG, Altmeyer P, von Kobyletzki G. Opposing effects of UVA1 phototherapy on the expression of bcl-2 and p53 in atopic dermatitis. *Arch Dermatol Res.* 2001 Apr;293(4):178-83.
24. Seguchi T, Cui CY, Kusuda S, Takahashi M, Aisu K, Tezuka T. Arch Dermatol Res. 1996 Jul;288(8):442-6. Decreased expression of filaggrin in atopic skin. *Acta Derm Venereol.* 1999 May;79(3):195-9.
25. Hannuksela-Svahn A, Paakko P, Autio P, Reunala T, Karvonen J, Vahakangas K. Expression of p53 protein before and after PUVA treatment in psoriasis. *Acta Derm Venereol.* 1999 May;79(3):195-9
26. A Soini Y, Kamel D, Paakko P, Lehto VP, Oikarinen A, Vahakangas KV. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. *Br J Dermatol.* 1994 Oct;131(4):514-20.
27. Healy E, Reynolds NJ, Smith MD, Harrison D, Doherty E, Campbell C, Rees JL. Up-regulation of p21^{WAF1/CIP1} in psoriasis and after the application of irritants and tape stripping. *J Invest Dermatol.* 1995 Aug;105(2):274-9.
28. O'Connor DP, Kay EW, Leader M, Murphy GM, Atkins GJ, Mabruk MJ. Altered p53 expression in benign and malignant skin lesions from renal transplant recipients and immunocompetent patients with skin cancer: correlation with human papillomaviruses? *Br J Dermatol.* 1994 Oct;131(4):514-20.
29. Sumitomo S, Kumasa S, Iwai Y, Mori M. Involucrin expression in epithelial tumors of oral and pharyngeal mucosa and skin. *Oral Surg Oral Med Oral Pathol.* 1986 Aug;62(2):155-63
30. Hashimoto T, Inamoto N, Nakamura K, Harada R. Involucrin expression in skin appendage tumours. *Br J Dermatol.* 1987 Sep;117(3):325-32
31. Motamed M, Powe D, Kendall C, Birchall JP, Banerjee AR. p53 Expression and keratinocyte hyperproliferation in middle ear cholesteatoma. *Clin Otolaryngol Allied Sci.* 2002 Dec;27(6):505-8
32. Albino AP, Reed JA, Bogdany JK, Sassoon J, Desloge RB, Parisier SC. Expression of p53 protein in human middle ear cholesteatomas: pathogenetic implications. *Am J Otol.* 1998 Jan;19(1):30-6.
33. Chae SW, Song JJ, Suh HK, Jung HH, Lim HH, Hwang J. Expression patterns of p27Kip1 and Ki-67 in cholesteatoma epithelium. *Laryngoscope.* 2000 Nov;110(11):1898-901.
34. Choufani G, Mahillon V, Decaestecker C, Lequeux T, Danguy A, Salmon I, Gabius HJ, Hassid S, Kiss R. Determination of the levels of expression of sarcolectin and calyculin and of the percentages of apoptotic but not proliferating cells to enable distinction between recurrent and nonrecurrent cholesteatomas. *Laryngoscope.* 1999 Nov;109(11):1825-31
35. Adamczyk M, Sudhoff H, Jahnke K. Immunohistochemical investigations on external auditory canal cholesteatomas. *Otol Neurotol.* 2003 Sep;24(5):705-8.
36. Huisman MA, De Heer E, Grote JJ. Cholesteatoma epithelium is characterized by increased expression of Ki-67, p53 and p21, with minimal apoptosis. *Acta Otolaryngol.* 2003 Apr;123(3):377-82.

37. Durko M, Kaczmarczyk D. Proliferation activity and apoptosis in granulation tissue and cholesteatoma in middle ear reoperations. *Folia Morphol (Warsz)*.2004 Feb;63(1):119-21.
38. Bernal Sprekelsen M, Ebmeyer J, Buchbinder A, Sudhoff H. Comparative analysis of the proliferative capacity of cholesteatomas *Acta Otorrinolaringol Esp*.2000 May;51(4):299-307.
39. Stammberger M, Bujia J, Kastenbauer E. Alteration of epidermal differentiation in middle ear cholesteatoma. *Am J Otol*. 1995 Jul;16(4):527-31
40. Huisman MA, de Heer E, Grote JJ. Terminal differentiation and MAPK signaling in human cholesteatoma epithelium. *Otology Neurology in press*
41. Caldwell CJ, Hobbs C, McKee PH. The relationship of Ki-67 and involucrin expression in proliferative, pre-neoplastic and neoplastic skin. *Clin Exp Dermatol*. 1997 Jan;22(1):11-6
42. Mallet Y, Nouwen J, Lecomte-Houcke M, Desaulty A. Aggressiveness and quantification of epithelial proliferation of middle ear cholesteatoma by MIB1. *Laryngoscope*. 2003 Feb;113(2):328-31.
43. Bujia J, Kim C, Ostos-Aumente P, Lopez-Villarejo J, Kastenbauer E. Enhanced epithelial proliferation due to elevated levels of interleukin-1 receptors in middle ear cholesteatomas. *Eur Arch Otorhinolaryngol*. 1997;254(1):6-8
44. Hoppe F. Proliferation behavior of cholesteatoma. *HNO*. 1995 Dec;43(12):710-5.
45. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. *Cell Death Differ*. 2001 Nov;8(11):1076-92
46. Yildirim MS, Ozturk K, Acar H, Arbag H, Ulku CH. Chromosome 8 aneuploidy in acquired cholesteatoma. *Acta Otolaryngol*.2003 Apr;123(3):372-6.
47. Lavezzi A, Mantovani M, Cazzulo A, Turconi P, Maturri L. ignificance of trisomy 7 related to PCNA index in cholesteatoma. *Am J Otolaryngol*. 1998 Mar-Apr;19(2):109-12.
48. Kinne RW, Kunisch E, Beensen V, Zimmermann T, Emmrich F, Petrow P, Lungershausen W, Hein G, Braun RK, Foerster M, Kroegel C, Winter R, Liesaus E, Fuhrmann RA, Roth A, Claussen U, Liehr T. Synovial fibroblasts and synovial macrophages from patients with rheumatoid arthritis and other inflammatory joint diseases show chromosomal aberrations. *Genes Chromosomes Cancer*. 2003 Sep;38(1):53-67.
49. Schilling V, Bujia J, Negri B, Kastenbauer E Interleukin-1-containing cells in cholesteatoma of the middle ear. *Laryngorhinootologie*. 1992 May;71(5):271-5.
50. Marenda SA, Aufdemorte TB. Localization of cytokines in cholesteatoma tissue. *Otolaryngol Head Neck Surg*. 1995 Mar;112(3):359-68.
51. Sudhoff H, Bujia J, Holly A, Kim C, Fisseler-Eckhoff A. Functional characterization of middle ear mucosa residues in cholesteatoma samples. *Am J Otol*. 1994 Mar;15(2):217-21.
52. Bujia J, Kim C, Ostos P, Sudhoff H, Kastenbauer E, Hultner L. Interleukin 1 (IL-1) and IL-1-receptor antagonist (IL-1-RA) in middle ear cholesteatoma: an analysis of protein production and biological activity. *Eur Arch Otorhinolaryngol*. 1996;253(4-5):252-5
53. Yan SD, Huang CC. Tumor necrosis factor alpha in middle ear cholesteatoma and its effect on keratinocytes in vitro. *Ann Otol Rhinol Laryngol*. 1991 Feb;100(2):157-61
54. Ergun S, Zheng X, Carlsoo B. Expression of transforming growth factor-alpha and epidermal growth factor receptor in middle ear cholesteatoma. *Am J Otol*. 1996 May;17(3):393-6.
55. Shiwa M, Kojima H, Moriyama H. Expression of transforming growth factor-alpha (TGF-alpha) in cholesteatoma. *J Laryngol Otol*. 1998 Aug;112(8):750-4
56. Akimoto R, Pawankar R, Yagi T, Baba S. Acquired and congenital cholesteatoma: determination of tumor necrosis factor-alpha, intercellular adhesion molecule-1, interleukin-1-alpha and lymphocyte functional antigen-1 in the inflammatory process. *ORL J Otorhinolaryngol Relat Spec*. 2000 Sep-Oct;62(5):257-65.
57. Sudhoff H, Dazert S, Gonzales AM, Borkowski G, Park SY, Baird A, Hildmann H, Ryan AF. Angiogenesis and angiogenic growth factors in middle ear cholesteatoma. *Am J Otol*. 2000 Nov;21(6):793-8.
58. Schmidt M, Grunsfelder P, Hoppe F. Up-regulation of matrix metalloprotease-9 in middle ear cholesteatoma, correlations with growth factor expression in vivo? *Eur Arch Otorhinolaryngol*. 2001 Nov;258(9):472-6.

59. Naim R, Riedel F, Hormann K. Expression of vascular endothelial growth factor in external auditory canal cholesteatoma. *Int J Mol Med*. 2003 May;11(5):555-8.
60. Bujia J, Holly A, Kim C, Schilling V, Kastenbauer E. New aspects on the pathogenesis of cholesteatoma: the possible role of immune cell-induced keratinocyte hyperproliferation. *Laryngorhinootologie*. 1993 Jun;72(6):279-83.
61. Ergun S, Zheng X, Carlsoo B. Expression of transforming growth factor-alpha and epidermal growth factor receptor in middle ear cholesteatoma. *Am J Otol*. 1996 May;17(3):393-6.
62. Lang S, Schilling V, Wollenberg B, Mack B, Nerlich A. Localization of transforming growth factor-beta-expressing cells and comparison with major extracellular components in aural cholesteatoma. *Ann Otol Rhinol Laryngol*. 1997 Aug;106(8):669-73.
63. Huisman MA, De Heer E, Grote JJ. Sustained extracellular signal-regulated kinase1/2 mitogen-activated protein kinase signalling is related to increased p21 expression in cholesteatoma epithelium. *Acta Otolaryngol*. 2005 Feb;125(2):134-40.
64. Shinoda H, Huang CC. Expressions of c-jun and p53 proteins in human middle ear cholesteatoma: relationship to keratinocyte proliferation, differentiation, and programmed cell death. *Laryngoscope*. 1995 Nov;105(11):1232-7.
65. Ottaviani F, Neglia CB, Berti E. Cytokines and adhesion molecules in middle ear cholesteatoma. A role in epithelial growth? *Acta Otolaryngol*. 1999;119(4):462-7.
66. Schonermark M, Mester B, Kempf HG, Blaser J, Tschesche H, Lenarz T. Expression of matrix-metalloproteinases and their inhibitors in human cholesteatomas. *Acta Otolaryngol*. 1996 May;116(3):451-6.
67. Banerjee AR, James R, Narula AA. Matrix metalloproteinase-2 and matrix metalloproteinase-9 in cholesteatoma and deep meatal skin. *Clin Otolaryngol Allied Sci*. 1998 Aug;23(4):345-7.
68. Banerjee AR, Jones JL, Birchall JP, Powe DG. Localization of matrix metalloproteinase 1 in cholesteatoma and deep meatal skin. *Otol Neurotol*. 2001 Sep;22(5):579-81.
69. Yang X, Li X, Ma M, Zhang L, Zhang Q, Wang J, Wang B. Expression of transforming growth factor-beta 1 matrix metalloproteinase-1 and its inhibitor in human middle ear cholesteatoma. *Zhonghua Er Bi Yan Hou Ke Za Zhi*. 2002 Apr;37(2):121-3.
70. Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M. Keratins and the keratinocyte activation cycle. *J Invest Dermatol*. 2001 May;116(5):633-40.
71. Kim HJ, Tinling SP, Chole RA. Expression patterns of cytokeratins in cholesteatomas: evidence of increased migration and proliferation. *J Korean Med Sci*. 2002 Jun;17(3):381-8.
72. Dallari S, Cavani A, Bergamini G, Girolomoni G. Integrin expression in middle ear cholesteatoma. *Acta Otolaryngol*. 1994 Mar;114(2):188-92.
73. Parisier SC, Agresti CJ, Schwartz GK, Han JC, Albino A. Alteration in cholesteatoma fibroblasts: induction of neoplastic-like phenotype. *Am J Otol*. 1993 Mar;14(2):126-30.
74. Chole RA, Faddis BT. Evidence for microbial biofilms in cholesteatomas. *Arch Otolaryngol Head Neck Surg*. 2002 Oct;128(10):1129-33.
75. Schroeder TH, Lee MM, Yacono PW, Cannon CL, Gerceker AA, Golan DE, Pier GB. CFTR is a pattern recognition molecule that extracts *Pseudomonas aeruginosa* LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. *Proc Natl Acad Sci US A*. 2002 May 14;99(10):6907-12.
76. Nell MJ, Grote JJ. Effects of bacterial toxins on air-exposed cultured human respiratory sinus epithelium. *Ann Otol Rhinol Laryngol*. 2003 May;112(5):461-8.
77. Levy O, Zarembek KA, Roy RM, Cywes C, Godowski PJ, Wessels MR. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. *J Immunol*. 2004 Oct 1;173(7):4627-34.
78. Shimizu T, Takahashi Y, Kawaguchi S, Sakakura Y. Hypertrophic and metaplastic changes of goblet cells in rat nasal epithelium induced by endotoxin. *Am J Respir Crit Care Med*. 1996 Apr;153(4 Pt 1):1412-8.
79. Harding KG, Morris HL, Patel GK. Science, medicine and the future: healing chronic wounds. *BMJ*. 2002 Jan 19;324(7330):160-3.
80. Chole RA, Hughes RM, Faddis BT. Keratin particle-induced osteolysis: a mouse model

- of inflammatory bone remodeling related to cholesteatoma. *J Assoc Res Otolaryngol.* 2001 Mar; 2(1): 65-71
81. Sudhoff H, Liebehenz Y, Aschenbrenner J, Jung J, Hildmann H, Dazert S. A murine model of cholesteatoma-induced bone resorption using autologous dermal implantation. *Laryngoscope.* 2003 Jun;113(6):1022-6.
 82. Fahey TJ 3rd, Turbeville T, McIntyre K. Differential TNF secretion by wound fibroblasts compared to normal fibroblasts in response to LPS. *J Surg Res.* 1995 Jun;58(6):759-64.
 83. Peek FA, Huisman MA, Berckmans RJ, Sturk A, Van Loon J, Grote JJ. Lipopolysaccharide concentration and bone resorption in cholesteatoma. *Otol Neurotol.* 2003 Sep;24(5):709-13.
 84. Barrick B, Campbell EJ, Owen CA. Leukocyte proteinases in wound healing: roles in physiologic and pathologic processes. *Wound Repair Regen.* 1999 Nov-Dec;7(6):410-22.
 85. Martin P. Wound healing-aiming for perfect skin regeneration. *Science.* 1997 Apr 4;276(5309):75-81.
 86. Baum CL, Arpey CJ. Normal cutaneous wound healing: clinical correlation with cellular and molecular events. *Dermatol Surg.* 2005 Jun;31(6):674-86;
 87. Iversen L, Johansen C, Kragballe K. Signal transduction pathways in human epidermis. *Eur J Dermatol.* 2005 Jan-Feb;15(1):4-12.
 88. Goliger JA, Paul DL. Wounding alters epidermal connexin expression and gap junction-mediated intercellular communication. *Mol Biol Cell.* 1995 Nov;6(11):1491-501.



Chapter 1

